Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, double-blind, placebo-controlled trial of oral BI 685509 in diabetic kidney disease
jRCT2031210055Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2021
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in diabetic glomerulosclerosis comparing BI 685509 arm with Placebo arm (2 arms). Primary endpoint: Change from baseline in log-transformed UACR at 20 weeks. Started Jun 2021; status: active, not recruiting.
02
Drugs
avenciguat
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on jRCT2031210055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210055.